Tuesday, October 27, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· June 22, 2026

Abaxx Continues to Provide Facts Refuting Ongoing Misinformation and Reaffirms Strong Business Fundamentals

View original at globenewswire.com
Abaxx Continues to Provide Facts Refuting Ongoing Misinformation and Reaffirms Strong Business Fundamentals Neither the Company nor its subsidiaries are under investigation by any regulatorUrges CIRO to investigate potentially manipulative or deceptive trading activity in Abaxx’s common sharesRetains leading U.S…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • New exchange markets exhibit natural growth patterns including low open interest relative to volume and trading dominated by incentive program participants building initial liquidity

    60% confidence
  • Through June 19, 2026, the average daily volume on Abaxx Exchange for June was 16,846 contracts per day, a 12% increase from May's 15,092

    60% confidence
  • Average daily open interest on Abaxx Exchange for June was 1,343, a 232% increase from May's 405

    60% confidence
  • None of the participants in Abaxx Exchange's market making and liquidity provider programs are undisclosed related parties

    60% confidence
  • Viceroy's reports amount to a short-and-distort campaign with the sole purpose of profiting from a decline in Abaxx's common share price at the expense of long-term shareholders

    60% confidence
  • Current cash is sufficient to fund operational plans for approximately the next seven quarters without raising additional funds

    60% confidence
  • Wash trading is illegal and not permitted on Abaxx Exchange pursuant to Rule 508 in the Exchange's rulebook

    60% confidence
  • Abaxx Exchange has a robust market surveillance program that actively monitors trading for signs of wash trading or market manipulation in alignment with regulatory requirements

    60% confidence
  • There are now 11 ISVs connected to Abaxx Exchange with 5 more in the pipeline

    60% confidence
  • The current net cash burn rate has averaged C$12.3 million over the past 2 completed quarters

    60% confidence
  • The Company holds more than C$97 million in cash and cash equivalents as of June 2026

    60% confidence
  • There are now 7 clearing firms connected to Abaxx Exchange with 14 more in the pipeline

    60% confidence
  • There are currently 22 brokers connected to Abaxx Exchange with 10 more in the pipeline

    60% confidence
  • Neither the Company nor its subsidiaries are under investigation by any regulator

    60% confidence
  • Suspected violations are subject to Abaxx Exchange's disciplinary proceedings under Rule 209, which can include reporting to regulators and suspension or termination of offending parties

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com